

This material is an English translation of the press release announced on March 29, 2017 in Japanese, and the Japanese release is given priority about the content and the interpretation.

---

March 29, 2017

**Announcement regarding the Recording of Extraordinary Loss (Impairment Loss)  
of the U.S. Subsidiary, Noven Pharmaceuticals, Inc.**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi; hereinafter referred to as "Hisamitsu") announces that goodwill impairment of the U.S. subsidiary, Noven Pharmaceuticals, Inc. (Head Office: Florida, USA; hereinafter referred to as "Noven") will be conducted.

1. Contents of the Extraordinary Loss (Impairment Loss)

Regarding the goodwill which arose upon acquisition of Noven in August 2009, as a result of consideration of the possibility to recover the goodwill in the future due to changes in Noven's business structure made in 2016, recording of the impairment loss has been decided.

2. The Amount Affecting Consolidated Profits and Losses Due to This Matter

Due to the effect of this matter, in the consolidated accounting of the fiscal year that ended in February 2017, the impairment loss of approximately 2.3 billion yen has been recorded as an extraordinary loss.



**Delivering Patch Culture Hand by Hand**

Hisamitsu Pharmaceutical Co., Inc. was established in 1847 and has marked its 170th anniversary since its foundation thanks to the support of many people.